US7153827B1
(en)
|
1994-03-08 |
2006-12-26 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2 and methods of use
|
US7186688B1
(en)
*
|
1994-03-08 |
2007-03-06 |
Human Genome Sciences, Inc. |
Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
|
US7109308B1
(en)
*
|
1994-03-08 |
2006-09-19 |
Human Genome Sciences, Inc. |
Antibodies to human vascular endothelial growth factor 2
|
US5932540A
(en)
|
1994-03-08 |
1999-08-03 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
US6734285B2
(en)
|
1994-03-08 |
2004-05-11 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2 proteins and compositions
|
US6608182B1
(en)
*
|
1994-03-08 |
2003-08-19 |
Human Genome Sciences, Inc. |
Human vascular endothelial growth factor 2
|
DK0751992T3
(da)
*
|
1994-03-08 |
2006-03-06 |
Human Genome Sciences Inc |
Karendotelvækstfaktor 2
|
US6040157A
(en)
*
|
1994-03-08 |
2000-03-21 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
US5928939A
(en)
*
|
1995-03-01 |
1999-07-27 |
Ludwig Institute For Cancer Research |
Vascular endothelial growth factor-b and dna coding therefor
|
US7160991B1
(en)
|
1995-03-02 |
2007-01-09 |
Ludwig Institute For Cancer Research |
Vascular endothelial growth factor polypeptides
|
EP0815221B1
(en)
*
|
1995-03-02 |
2003-10-22 |
AMRAD Operations Pty.,Ltd. |
A novel growth factor and a genetic sequence encoding same
|
US7429646B1
(en)
|
1995-06-05 |
2008-09-30 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor-like 2
|
CA2224002A1
(en)
*
|
1995-06-06 |
1996-12-12 |
Human Genome Sciences, Inc. |
Human vascular endothelial growth factor 3
|
US7423125B2
(en)
|
1995-08-01 |
2008-09-09 |
Vegenics Limited |
Antibodies to VEGF-C
|
ES2202469T5
(es)
|
1995-09-08 |
2011-06-06 |
Genentech, Inc. |
Proteína relacionada con el vegf.
|
ES2341864T3
(es)
|
1995-09-29 |
2010-06-29 |
Universita Degli Studi Di Siena |
Genes regulados y usos de los mismos.
|
WO1997017442A1
(en)
|
1995-11-08 |
1997-05-15 |
Immunex Corporation |
Flk-1 binding protein
|
US6994989B1
(en)
|
1995-11-08 |
2006-02-07 |
Immunex Corp. |
FLK-1 binding proteins
|
US6713061B1
(en)
|
1996-03-12 |
2004-03-30 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
US7357927B2
(en)
|
1996-03-12 |
2008-04-15 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
WO1997033904A1
(en)
|
1996-03-12 |
1997-09-18 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
US6635743B1
(en)
|
1996-03-22 |
2003-10-21 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule II and methods of use
|
US7964190B2
(en)
|
1996-03-22 |
2011-06-21 |
Human Genome Sciences, Inc. |
Methods and compositions for decreasing T-cell activity
|
ES2251740T3
(es)
|
1996-08-23 |
2006-05-01 |
Ludwig Institute For Cancer Research |
Factor de crecimiento de celulas de endotelio vascular d recombinante (vegf-d).
|
AU5439998A
(en)
*
|
1996-12-06 |
1998-06-29 |
Zymogenetics Inc. |
Vascular endothelial growth factor
|
ZA9711456B
(en)
*
|
1996-12-20 |
1998-06-30 |
Ludwig Inst Cancer Res |
VEGF-B/receptor complex and uses thereof.
|
ATE296117T1
(de)
|
1997-03-07 |
2005-06-15 |
Wistar Inst |
Verwendung von adenoviralen vektoren, die pdgf oder vegf exprimieren, zur heilung von gewebsdefekten und zur induzierung der hypervaskulität in säugergeweben
|
CN1260835A
(zh)
*
|
1997-04-25 |
2000-07-19 |
科莱特诺医疗公司 |
截短的vegf相关蛋白质
|
US6281175B1
(en)
|
1997-09-23 |
2001-08-28 |
Scimed Life Systems, Inc. |
Medical emulsion for lubrication and delivery of drugs
|
WO1999040197A2
(en)
|
1998-02-06 |
1999-08-12 |
Collateral Therapeutics, Inc. |
Variants of the angiogenic factor vascular endothelial cell growth factor: vegf
|
DE19813774A1
(de)
*
|
1998-03-27 |
1999-09-30 |
Max Planck Gesellschaft |
Parapockenvirus-kodierter vaskulärer Endothelzell Wachstumsfaktor (PPV-VEGF)
|
US20030118567A1
(en)
*
|
1999-03-26 |
2003-06-26 |
Stewart Duncan John |
Cell-based therapy for the pulmonary system
|
NZ511379A
(en)
|
1998-11-10 |
2003-06-30 |
Ludwig Inst Cancer Res |
Platelet-derived growth factor D (PDGF-D), DNA coding therefor, and uses thereof for invasions of tumor cells
|
US6783953B1
(en)
|
1998-12-22 |
2004-08-31 |
Janssen Pharmaceutica N.V. |
Vascular endothelial growth factor-X
|
EP1147193A4
(en)
*
|
1999-01-29 |
2003-01-22 |
Ludwig Inst Cancer Res |
GROWTH FACTOR H OF PLATELET ORIGIN GROWTH FACTOR / VASCULAR ENDOTHELIUM GROWTH FACTOR AND USES THEREOF
|
US7223724B1
(en)
|
1999-02-08 |
2007-05-29 |
Human Genome Sciences, Inc. |
Use of vascular endothelial growth factor to treat photoreceptor cells
|
EP2357192A1
(en)
|
1999-02-26 |
2011-08-17 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
JP2004513328A
(ja)
*
|
1999-03-03 |
2004-04-30 |
ルードヴィッヒ インスティテュート フォー キャンサー リサーチ |
血管内皮増殖因子(vegf−b)欠損動物の心臓異常及びこれら心臓異常に関する方法
|
WO2000064261A1
(en)
*
|
1999-04-26 |
2000-11-02 |
Ludwig Institute For Cancer Research |
Role of vascular endothelial growth factor-b (vegf-b) in developing bones and uses thereof
|
EP1183358A1
(en)
*
|
1999-06-07 |
2002-03-06 |
Edwards Lifesciences Corporation |
Targeted angiogenesis
|
US8188043B2
(en)
*
|
1999-07-28 |
2012-05-29 |
The Board Of Trustees Of The Leland Stanford Jr. University |
Nicotine in therapeutic angiogenesis and vasculogenesis
|
ES2313900T3
(es)
*
|
1999-07-28 |
2009-03-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Nicotina en angiogenesis y vasculogenesis terapeutica.
|
ATE412427T1
(de)
*
|
2000-02-02 |
2008-11-15 |
Us Health |
Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff
|
AUPQ568100A0
(en)
*
|
2000-02-16 |
2000-03-09 |
Amrad Operations Pty. Limited |
A method for producing recombinant molecules
|
DE60131146T2
(de)
|
2000-02-25 |
2008-03-06 |
Ludwig Institute For Cancer Research |
Material und verfahren die hybridvaskularendothelwachstumfaktoren dns und proteine enthalten und screeningverfahren für modulatoren
|
AUPQ592100A0
(en)
*
|
2000-02-29 |
2000-03-23 |
Council Of The Queensland Institute Of Medical Research, The |
A method of treatment and prophylaxis
|
US20030104977A1
(en)
*
|
2000-03-31 |
2003-06-05 |
Ugo Ripamonti |
Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
|
EP2267026A1
(en)
|
2000-04-12 |
2010-12-29 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US6670125B2
(en)
*
|
2000-05-17 |
2003-12-30 |
Ludwig Institute For Cancer Research |
Methods for detecting for the presence of tumor cells and for screening for anti-tumor agents
|
AU2001280841A1
(en)
*
|
2000-07-26 |
2002-02-05 |
Licentia Ltd. |
Glycosylated VEGF-B and method for increasing the amount of soluble VEGF-B
|
AU8473401A
(en)
*
|
2000-08-04 |
2002-02-18 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
WO2002029087A2
(en)
*
|
2000-10-02 |
2002-04-11 |
St. Elizabeth's Medical Center Of Boston, Inc. |
Use of lymphangiogenic agents to treat lymphatic disorders
|
AU2002224471A1
(en)
*
|
2000-11-01 |
2002-05-15 |
Aventis Pharma S.A. |
In vivo stimulation of angiogenic activity
|
US7067317B2
(en)
*
|
2000-12-07 |
2006-06-27 |
Sangamo Biosciences, Inc. |
Regulation of angiogenesis with zinc finger proteins
|
AU2884102A
(en)
*
|
2000-12-07 |
2002-06-18 |
Sangamo Biosciences Inc |
Regulation of angiogenesis with zinc finger proteins
|
US7611711B2
(en)
|
2001-01-17 |
2009-11-03 |
Vegenics Limited |
VEGFR-3 inhibitor materials and methods
|
US20070111944A1
(en)
*
|
2001-02-16 |
2007-05-17 |
Scrofani Sergio D B |
Purification of vascular endothelial growth factor-B
|
US20070050857A1
(en)
*
|
2001-02-28 |
2007-03-01 |
Hayward Nick K |
Method of treatment and prophylaxis
|
AU2002303261A1
(en)
*
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene brcc2 and diagnostic and therapeutic uses thereof
|
US20050232921A1
(en)
*
|
2001-04-13 |
2005-10-20 |
Rosen Craig A |
Vascular endothelial growth factor 2
|
AU2002256172A1
(en)
*
|
2001-04-13 |
2002-10-28 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
DE60236646D1
(de)
|
2001-04-13 |
2010-07-22 |
Human Genome Sciences Inc |
Anti-VEGF-2 Antikörper
|
US7402312B2
(en)
*
|
2001-04-13 |
2008-07-22 |
Human Genome Sciences, Inc. |
Antibodies to vascular endothelial growth factor 2 (VEGF-2)
|
EP1385862A4
(en)
*
|
2001-04-13 |
2005-03-02 |
Human Genome Sciences Inc |
VASCULAR ENDOTHEL GROWTH FACTOR 2
|
CA2444578C
(en)
*
|
2001-04-24 |
2010-12-14 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Use of hypoxia inducible factor 2alpha for curing neonatal respiratory distress syndrome and as a target for the treatment of pulmonary hypertension
|
JP2005505510A
(ja)
*
|
2001-06-20 |
2005-02-24 |
ルードヴィッヒ インスティテュート フォー キャンサー リサーチ |
Vegf−bによる血管新生の刺激
|
US20050271663A1
(en)
*
|
2001-06-28 |
2005-12-08 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
EP1399484B1
(en)
*
|
2001-06-28 |
2010-08-11 |
Domantis Limited |
Dual-specific ligand and its use
|
CN1555488A
(zh)
*
|
2001-07-12 |
2004-12-15 |
路德维格癌症研究院 |
淋巴管内皮细胞物质及方法
|
US7217570B2
(en)
|
2001-08-23 |
2007-05-15 |
The Wistar Institute Of Anatomy And Biology |
Organotypic intestinal culture and methods of use thereof
|
US20030113324A1
(en)
|
2001-10-01 |
2003-06-19 |
Kari Alitalo |
Neuropilin/VEGF-C/VEGFR-3 materials and methods
|
US20040214766A1
(en)
*
|
2001-10-01 |
2004-10-28 |
Kari Alitalo |
VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
|
PT1463751E
(pt)
|
2001-12-21 |
2013-08-26 |
Human Genome Sciences Inc |
Proteínas de fusão de albumina
|
US20030221931A1
(en)
*
|
2002-02-28 |
2003-12-04 |
Steve Marsh |
Sliding device
|
CA2429483A1
(en)
*
|
2002-05-17 |
2003-11-17 |
Amrad Operations Pty Ltd. |
Immunointeractive molecules
|
EP1912069A3
(en)
|
2002-06-05 |
2008-07-09 |
Sopherion Therapeutics, Inc. |
Method to screen ligands using eukaryotic cell display
|
AU2003237456A1
(en)
*
|
2002-06-05 |
2003-12-22 |
Sopherion Therapeutics, Inc. |
Method to screen ligands using eukaryotic cell display
|
US20030232439A1
(en)
*
|
2002-06-17 |
2003-12-18 |
Isis Pharmaceuticals Inc. |
Antisense modulation of VEGF-B expression
|
US9321832B2
(en)
*
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
ATE328906T1
(de)
*
|
2002-06-28 |
2006-06-15 |
Domantis Ltd |
Dual-specifische liganden mit erhöhter halbwertszeit
|
US7696320B2
(en)
|
2004-08-24 |
2010-04-13 |
Domantis Limited |
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
|
US7479270B2
(en)
|
2002-07-23 |
2009-01-20 |
Vegenics Limited |
Methods and compositions for activating VEGF-D and VEGF-C
|
WO2004052177A2
(en)
*
|
2002-12-05 |
2004-06-24 |
Case Western Reserve University |
Cell-based therapies for ischemia
|
US7470538B2
(en)
*
|
2002-12-05 |
2008-12-30 |
Case Western Reserve University |
Cell-based therapies for ischemia
|
EP1578801A2
(en)
*
|
2002-12-27 |
2005-09-28 |
Domantis Limited |
Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
|
WO2004070018A2
(en)
*
|
2003-02-04 |
2004-08-19 |
Ludwig Institute For Cancer Research |
Vegf-b and pdgf modulation of stem cells
|
EP3168304A1
(en)
|
2003-08-27 |
2017-05-17 |
Ophthotech Corporation |
Combination therapy for the treatment of ocular neovascular disorders
|
EP1560025A3
(en)
*
|
2003-10-03 |
2011-09-07 |
F. Hoffmann-La Roche AG |
Specific markers for diabetes
|
JP2007517042A
(ja)
|
2003-12-30 |
2007-06-28 |
デュレクト コーポレーション |
活性物質、好ましくはgnrhの制御放出のための、好ましくはpegおよびplgの混合物を含有するポリマーインプラント
|
US20050214280A1
(en)
*
|
2004-03-02 |
2005-09-29 |
Ludwig Institute For Cancer Research |
Method for inhibiting tumor formation and growth
|
WO2005087812A1
(en)
*
|
2004-03-05 |
2005-09-22 |
Ludwig Institute For Cancer Research |
Multivalent antibody materials and methods for vegf/pdgf family of growth factors
|
WO2005087177A2
(en)
*
|
2004-03-05 |
2005-09-22 |
Ludwig Institute For Cancer Research |
Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same
|
WO2005099771A2
(en)
*
|
2004-04-08 |
2005-10-27 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating neuropathic and neurodegenerative conditions
|
CA2575901C
(en)
*
|
2004-08-02 |
2015-01-27 |
Amrad Operations Pty. Ltd. |
A method of treating cancer comprising a vegf-b antagonist
|
US7595149B1
(en)
|
2004-11-08 |
2009-09-29 |
University Of Kentucky Research Foundation |
Methods for cancer detection
|
US7358085B2
(en)
*
|
2005-02-28 |
2008-04-15 |
Sangamo Biosciences, Inc. |
Anti-angiogenic methods and compositions
|
JP2008537752A
(ja)
*
|
2005-04-12 |
2008-09-25 |
イントラディグム コーポレイション |
がんおよび他の新血管形成疾患を処置するためのRNAi治療用の組成物および方法
|
US7893244B2
(en)
*
|
2005-04-12 |
2011-02-22 |
Intradigm Corporation |
Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
|
ATE502956T1
(de)
|
2005-08-15 |
2011-04-15 |
Vegenics Pty Ltd |
Modifizierte vegf und pdgf mit verbesserten angiogenen eigenschaften
|
AU2006321364B2
(en)
*
|
2005-12-01 |
2011-11-10 |
Domantis Limited |
Noncompetitive domain antibody formats that bind Interleukin 1 Receptor type 1
|
DK2548578T3
(da)
|
2006-05-17 |
2014-10-06 |
Ludwig Inst Cancer Res |
Målretning af VEGF-B-regulering af fedtsyretransportører til modulering af humane sygdomme
|
WO2008085229A2
(en)
*
|
2006-11-15 |
2008-07-17 |
Arteriocyte Inc. |
Cell-based therapies for treating liver disease
|
JP2010528647A
(ja)
*
|
2007-06-06 |
2010-08-26 |
ドマンティス リミテッド |
ポリペプチド、抗体可変ドメインおよびアンタゴニスト
|
US7819579B2
(en)
*
|
2007-11-26 |
2010-10-26 |
Schmulenson Harold K |
Radiation sensing device and holder
|
WO2009075565A1
(en)
*
|
2007-12-12 |
2009-06-18 |
Erasmus University Medical Center Rotterdam |
Methods for controlling vasculogenesis
|
NZ586544A
(en)
|
2007-12-26 |
2012-07-27 |
Vaccinex Inc |
Anti-c35 antibody in combination with an ani-her2 antibody in cancer therapies and methods
|
EP2271365A4
(en)
*
|
2008-04-09 |
2011-10-26 |
Ludwig Inst Cancer Res |
REGULATION OF FATTY ACID TRANSPORTERS
|
IL205774A0
(en)
*
|
2010-05-13 |
2010-12-30 |
Muhammad Abdulrazik |
Novel compounds for the treatment of glaucoma and ocular hypertension
|
KR101335203B1
(ko)
*
|
2010-03-26 |
2013-11-29 |
숙명여자대학교산학협력단 |
혈관신생촉진용 펩타이드 및 이의 용도
|
WO2011154308A1
(en)
|
2010-06-08 |
2011-12-15 |
Proyecto De Biomedicina Cima, S.L. |
New compositions and cell therapy methods for the treatment of cirrhosis
|
RU2477529C2
(ru)
*
|
2011-04-28 |
2013-03-10 |
Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" |
Способ коррекции эндотелиальной дисфункции раствором гомеопатических разведений антител к эндотелиальной синтазе оксида азота человека
|
AU2014286996A1
(en)
|
2013-07-12 |
2016-01-07 |
Iveric Bio, Inc. |
Methods for treating or preventing ophthalmological conditions
|
KR20160096194A
(ko)
*
|
2013-12-18 |
2016-08-12 |
씨에스엘 리미티드 |
상처 치료 방법
|
CN107537026A
(zh)
*
|
2017-08-31 |
2018-01-05 |
中山大学中山眼科中心 |
Vegf‑b的应用
|
CN107661492A
(zh)
*
|
2017-08-31 |
2018-02-06 |
中山大学中山眼科中心 |
Vegf‑b的新用途
|
US10745454B2
(en)
*
|
2018-01-31 |
2020-08-18 |
Seyed Mohsen Asghari |
Method of synthesizing antagonist peptides for cell growth
|
CN109337931A
(zh)
*
|
2018-11-02 |
2019-02-15 |
东北师范大学 |
Vegfb基因的应用及vegfb肿瘤诱导和肿瘤抑制动物模型的构建方法
|
CN110777146A
(zh)
*
|
2019-11-28 |
2020-02-11 |
南通大学 |
一种pdgfb启动子活性报告质粒的构建方法
|